GALEGENIMAB
UNII UTI65JH23L

Substance Identification & Data

This profile provides standardized clinical and technical data for Galegenimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) UTI65JH23L.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2403683-24-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

UTI65JH23L

CAS Registry Number

2403683-24-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

GALEGENIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C184864

National Cancer Institute reference terminology for clinical and research data.

INN ID

11632

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-62

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Galegenimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

GALEGENIMAB

Common Names & Synonyms

GALEGENIMAB [INN]

GALEGENIMAB [USAN]

GALEGENIMAB [WHO-DD]

IMMUNOGLOBULIN FAB G1-KAPPA, ANTI-(HOMO SAPIENS HTRA1 (HTRA SERINE PEPTIDASE 1, PROTEASE SERINE 11 (IGF BINDING), PRSS11, IGFBP5-PROTEASE, ARMD7)), HUMANIZED MONOCLONAL ANTIBODY; VH-(CH1-HINGE) GAMMA1 HEAVY CHAIN HUMANIZED (1-223) (VH (HOMO SAPIENS IGHV1-46*01 (77.6%) -(IGHD) - IGHJ4*01 (92.9%), CDR-IMGT (8.8.12) (26-33.51-58.97-108)) (1-119) -CH1- HINGE (HOMO SAPIENS IGHG1*01 (100%), G1M17 (CH1 K120 (216) (120-217), HINGE 1-7 (218-223)) (120-223)), (222-213')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-213') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (84.2%) - IGKJ1*01 (100%), CDR-IMGT (5.3.9) (27-31.49-51.88-96)) (1'-106') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (152), V101 (190) (107'-213')), PRODUCED IN THE BACTERIA ESCHERICHIA COLI (E. COLI), NON-GLYCOSYLATED

IMMUNOGLOBULIN IGG1 FAB FRAGMENT, ANTI-(HUMAN SERINE PROTEINASE HTRA1) (HUMAN-MUS MUSCULUS MONOCLONAL FHTR2163 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL FHTR2163 .KAPPA.-CHAIN